BackTable / Urology / Podcast / Episode #63
Multidisciplinary Management of RCC
with Dr. Rana McKay and Dr. Raquibul Hannan
In this special episode, Dr. Phil Pierorazio (University of Pennsylvania) invites Dr. Rana McKay (UC San Diego) and Dr. Raquibul Hannan (UT Southwestern) about treatment options for renal cell carcinoma (RCC) patients in preparation for the 2022 International Kidney Cancer Symposium in Austin, Texas.
BackTable, LLC (Producer). (2022, November 4). Ep. 63 – Multidisciplinary Management of RCC [Audio podcast]. Retrieved from https://www.backtable.com
Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.
Stay Up To Date
Dr. Rana McKay
Dr. Rana McKay is a medical oncologist and associate professor at UC San Diego Health in California.
Dr. Raquibul Hannan
Dr. Raquibul Hannan is the chief of the genitourinary radiation oncology service at UT Southwestern in Dallas, Texas.
Dr. Phil Pierorazio
Dr. Phil Pierorazio is the chief of urology with the Pennsylvania Presbyterian Medical Center at the University of Pennsylvania.
First, the doctors discuss their excitement for the 2022 IKCS. They have benefited greatly from participating in collaboration and networking, improving their wellness strategies, learning about new clinical trials, and debating difficult cases at academic conferences like IKCS.
Next, Dr. Pierorazio presents four different difficult RCC classes to the doctors and asks for an outline of their treatment plans. He starts with localized disease and works towards more aggressive and nodally invasive cancer. For each case, Dr. McKay and Dr. Hannan explain recent developments in clinical trial data, side effect considerations, and the importance of assessing patient comorbidities. All three doctors draw conclusions based on their previous patients as well. Additionally, Dr. McKay explains why it is important to understand what the patient understands about their cancer diagnosis before presenting these treatment options to patients. Dr. Pierorazio has learned to ask patients about their greatest cancer-related fear in order to guide his treatment decisions. Dr. Hannan advises doctors to look at the failure rates of clinical trials along with the success rates.
Localized clear cell RCC patient with 1 kidney
Adjuvant chemotherapy for a post-nephrectomy patient with T3a clear cell RCC
Papillary RCC patient with a 10 cm mass and a 10 cm para aortic lymph node
Chromophobe RCC patient with an 8 cm renal mass and spinal metastasis
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.